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period, FAST scores were signiﬁ cantly correlated with individual symptoms, impact
on daily activities and sleep, and ﬂ ushing-related dissatisfaction (p  0.01). Changes 
in FAST scores were associated with treatment satisfaction (p  0.01) and patient/phy-
sician-rated OTE (p  0.01). Responders, deﬁ ned by improved OTE ratings, experi-
enced greater improvements than non-responders (p  0.01) in maximum (1.85 points 
vs. 0.18 points) and mean (0.51 points vs. 0.15 points) overall ﬂ ushing severity
scores. Among patients with ﬂ ushing, mean FAST scores differed between those who 
subsequently discontinued due to ﬂ ushing (7.9/10 points) vs. those who did not (4.7/10
points; p  0.001). The probable range in this study for a detectable change in ﬂ ushing 
symptoms (MID) was 0.29–0.38 points for mean overall ﬂ ushing severity and 0.41–
0.54 points for maximum overall ﬂ ushing severity. CONCLUSIONS: The FAST is a
new instrument designed to assess the symptoms and impact of niacin-induced ﬂ ush-
ing. The FAST exhibited test-retest reliability and substantial evidence of construct 
validity among patients with dyslipidemia. Overall, ﬂ ushing severity was responsive 
to change over time, suggesting that the FAST is a useful instrument for evaluating
ﬂ ushing symptoms induced by niacin therapy.
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OBJECTIVES: Measuring patients subjective health status (HS) has become accepted
in cardiology. However, the effect of these measurements on outcome and well-being
of heart failure patients remains unclear. METHODS: The aim of this study was to
investigate the impact of measuring HS on intermediate patients’ well-being. In two
Austrian heart failure outpatient wards 175 patients with documented heart failure 
were randomized into an intervention (IG) and control group (CG). Patients HS in
the IG was measured prior to the physician contact using the Short-Form 36 and 
Hospital Anxiety and Depression Scale. IG-patients received feedback electronically
feedback on their individual HS. The results were also made available to the treating 
physicians. They were encouraged to give additional feedback or to apply results for
auxiliary treatment planning (e.g., counselling). Patients in CG received usual care
without measuring HS prior to the physicians visit. After the visit, patients in both
groups rated their health-related quality of life (HRQL) and general health on the 
MacNew Heart Disease HRQL Instrument. Patients were reassessed by postal ques-
tionnaire six months after initial visit. RESULTS: Complete 6-month follow-up data
was available for 139 patients (79% response rate; 25.3% female; age: 58 o 13.2;
64.2% retired; NYHA I: 14.7%, NYHA II: 53.9%, NYHA III: 24.5%, NYHA IV: 
6.9%). Physical HRQL signiﬁ cantly deteriorated in both groups (IG: 0.3; CG: 0.4, 
both p  .01), whereas no signiﬁ cant deterioration for emotional and social HRQL 
was reported by the IG (IG: 0.1; 0.1, p  ns). Overall health improved in 34% of 
the IG patients, but only in 22% of the CG patients [ARR  12%, p  0.09; NNT of 
9]. CONCLUSIONS: Routine assessment of patients subjective HS appears to be
beneﬁ cial in helping maintain the well-being of heart failure patients (NNT  9), which 
naturally decreases over time. These results, however, need to be replicated in an ade-
quately powered study [N  211,á  .005, 1-â  0.89].
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OBJECTIVES: Although payers are asking for comparative effectiveness data, risk of 
conducting studies is signiﬁ cant. One possible intermediary step is to leverage a vali-
dated instrument, the Treatment Satisfaction Questionnaire for Medication Version 
1.4 (TSQM), to identify domains for separation and calculate sample size required for 
superiority in a comparative study. METHODS: We used data from iGuard.org, a
consumer drug safety service totaling over 1 million members, whereby patients are
randomly invited to complete the TSQM on an on-going basis. TSQM is a 14-item 
reliable and valid instrument providing scores on four scales—effectiveness, side 
effects, convenience and global satisfaction. For this study, we analyzed all responses 
from patients using lisinopril and metoprolol. For sample size evaluation, adjusted 
means (LsMean) and standard errors (SE) were generated for each treatment using an 
analysis of covariance model controlling for: patient age; gender; self-reported severity 
of disease; and use of other hypertensive, diabetes and heart failure medications.
RESULTS: A total of 625 patients, 363 (58.1%) on lisinopril and 262 (41.9%) on 
metoprolol completed the TSQM between March and November 2008. TSQM
domains had good internal consistency with Cronbach’s alpha values over 0.85. There
were signiﬁ cant differences between the two treatments on age; self-reported severity; 
and use of diabetes and heart failure medications. LsMean (SE) for lisinopril and
metoprolol was 68.80 (1.46) and 66.01 (1.53) on effectiveness; 90.72 (1.83) and 85.66 
(1.91) on side effects; 87.09 (1.28) and 81.55 (1.34) on convenience; and 67.67 (1.78) 
and 62.92 (1.86) on global satisfaction, respectively. Given differences observed, a 
sample size of 640 per treatment would be required to detect a statistically signiﬁ cant
difference at a two-sided alpha of 0.05 with 80% power. CONCLUSIONS: This 
obtains feedback on comparative effectiveness study design and risk by conducting a
pre-study that administers a validated instrument to an on-line community.
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OBJECTIVES: The purpose of this study is to assess: 1) the impact of different educa-
tion modules (class education, mail education or both) on Hemoglobin A1c control 
in diabetic patients with hypertension; 2) determine which education module was the
most effective for patient disease process awareness based on Knowledge Tool Test
scores. METHODS: Adult patients with type-2 Diabetes with concomitant hyperten-
sion were recruited from community based primary care physician ofﬁ ces. The study 
was composed of 825 diabetic patients, a subset of those enrolled in the Baltimore 
Partnership Programs to Reduce CVD Disparities project based on a minimum of one 
year of follow-up. Intervention patients received education either by class, mail, or 
both. HbA1c was measured at baseline and patients were followed-up every six 
months. Multiple regression models were used to assess the effects of 1) Different 
education modules on HbA1c change, deﬁ ned as percent change of HbA1c from
baseline; 2) different education modules on change of patients’ disease process aware-
ness, deﬁ ned as change of Knowledge Tool Test score from the baseline. The model
was adjusted for sociodemographic variables. RESULTS: The majority of the diabetic 
patients were African American (88.61%), females (65.62%), and the mean age was
65 years. The mean HbA1c reduction was 0.8. As compared to the control patients 
(0.7), the HbA1c reduction was larger in intervention patients (0.9). Males (0.82 
vs. 0.78) had a higher reduction in HbA1c values than females. Opposite trends were
found on patient disease process awareness. CONCLUSIONS: In this patient sample,
decreased trend in HbA1c level and an increased trend in Knowledge Tool Test score 
is seen among intervention patients, with class education module being more effective 
in patient disease process awareness. These results may help guide future patient
intervention programs for diabetes and hypertension management.
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OBJECTIVES: Consumer directed health plans (CDHP) are aimed at reducing moral
hazard due to insurance coverage. How do CDHP plans affect the consumption of 
pharmaceuticals for chronic diseases such as hypertension, high cholesterol and
diabetes? METHODS: We obtained data on all employees from a large private U.S.
employer for the 2005 to 2007 time period. All enrollees in the CDHP plan in this 
study are initially provided an employer funded Health Reimbursement Account 
(HRA) from which they can purchase medical care. Funds in these accounts range
from $1000 to $2000 depending on whether the enrollee is in an individual or a family 
health plan. After the HRA funds are exhausted, there is a second phase in which 
enrollee spending is completely out of pocket (range from $500 to $2000), after which
time the insurance plan begins coverage. We compare average daily pharmaceutical 
spending for individuals with diabetes, hypertension and high cholesterol as they move
through each of the different coverage thresholds(HRA, Out-of-Pocket and Full-
Coverage). RESULTS: Using Icd-9 codes we identiﬁ ed 27,644 individuals diagnosed
with diabetes, hypertension or high-cholesterol. For each of these diseases average 
daily pharmaceutical expenditure was substantially lower when individuals were in
the HRA and out-of-pocket sections of their CDHP plan as compared to when they 
were in the Full-Coverage part of their insurance plan. Average daily expenditure on 
pharmaceuticals was approximately $2.60 for individuals in the HRA section of the 
plan, $1.00 for individuals who moved into the out-of-pocket part of the insurance 
plan and $4.00 for individuals who were covered by insurance. CONCLUSIONS:
Findings from this study suggest that cost-sharing levels in CDHP plans affect phar-
maceutical spending on the treatment of chronic diseases. Reductions in chronic
disease pharmaceutical expenditures have the potential to negatively affect enrollee
health outcomes.
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OBJECTIVES: Discover if age-, gender-, race-, or income-related disparities in care 
for coronary artery disease (CAD) exist among Medicare enrollees with supplement 
plan coverage (i.e. Medigap). METHODS: Data were obtained from UnitedHealth
Group’s database of AARP Medigap enrollees. Patients were selected into the study 
if they had one or more medical claims with a diagnosis of CAD from July 1, 2006-
June 30, 2007. Logistic regression analyses tested for age-, gender-, race-, or income-
related differences in the likelihood of receiving an ofﬁ ce visit, coronary angiography,
or surgical intervention. The regression models controlled for socioeconomics, health 
